Go back to /resources
Back
Clinical Guidelines
Updated CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease
November 23, 2021
The Canadian Rheumatology Association guideline panel suggests using COVID-19 vaccination in persons aged 12 and older with autoimmune rheumatic disease...
Additional Resources
Decision Tool for COVID-19 Vaccination
The CRA, with input from the Canadian Arthritis Patient Alliance (CAPA) has developed a Decision Tool for COVID-19 Vaccination in Patients with Autoimmune Rheumatic Diseases. Updates to the Tool include the addition of all vaccines currently approved for use by Health Canada, as well as a section on pediatric considerations. You may reproduce and distribute an unedited copy of this document without additional permission.
Related Resources
View All
Clinical Guidelines
CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and […]
April 23, 2026
Clinical Guidelines
Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Guideline for the Management of Axial Spondyloarthritis
The management of axial spondyloarthritis (axSpA) is a complex and rapidly changing field for Canadian rheumatologists. The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Rheumatology Association (CRA) last updated treatment recommendations for the management of axSpA in 2014(1,2). […]
April 22, 2026
Clinical Guidelines
CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors
This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]
September 1, 2025